by Vanessa G. Oliveira  , Ana Filipa Saraiva  , Fátima Costa  and Aida Botelho de Sousa

Received: 27 February 2019;  Published: 24 September 2019;  doi: 10.21926/obm.transplant.1903086

Nowadays, hematopoietic stem cell transplantation (HSCT) is a common procedure in hematology units within reference centers, mainly for the treatment of hematological malignancies such as multiple myeloma, lymphoma, and acute leukemia. Nevertheless, HSCT has much wider applications, namely in autoimmune diseases, congenital metabolic defects, and hemoglobinopathies. Thalassemia major and sickle cell disease make up the most frequent hereditary hemoglobinopathies worldwide. Despite advances on the prevention and tre [...]

by Anita Modi  and Sherif Beniameen Mossad

Received: 07 July 2019;  Published: 06 September 2019;  doi: 10.21926/obm.transplant.1903085

Chronic inflammatory states lead to T cell exhaustion, characterized by reduced T cell proliferation and activity. Immune checkpoint inhibitors (ICPI) reactivate T cells to restore the immune system’s natural defenses against foreign antigens. The widespread use of these agents in the treatment of malignancy has led to markedly reduced tumor burden and improved patient survival, sparking curiosity about their potential role in the treatment of other chronic inflammatory states, including infectious diseases. While [...]

by Salim Hamdani  and Daniel Azoulay

Received: 18 April 2019;  Published: 04 September 2019;  doi: 10.21926/obm.transplant.1903084

The privileged liver, due to its immunological status, is referred to as a tolerogenic organ. However, this alone does not explain the introduction of tolerance after single or combined liver transplantation (kidney, heart, pancreas, and intestine); other factors, such as recipient’s age, donor’s hepatic volume, iron metabolism, biomarkers, or imprint of cytomegalovirus infection, appear to be involved in the identification of patients who are likely to be tolerant to their graft. All the afore-stated factors appea [...]

by Qing Ye  , Yijen L. Wu  , Lesley M. Moley  , Parker H. Mills  , Fang-Cheng Yeh  , Haosen Zhang  , Danielle F. Eytan  , Li Liu  , T. Kevin Hitchens  and Chien Ho

Received: 07 January 2019;  Published: 29 August 2019;  doi: 10.21926/obm.transplant.1903083

Background: Cardiac allograft vasculopathy (CAV) remains a major obstacle to long-term heart allograft survival. A number of studies show that immune mechanisms are involved in CAV. Using non-invasive cellular MRI (CMRI) to explore indicators of CAV lesions and characterize its development could provide new insights into the target immune cells that are responsible for the progression of CAV and reveal early markers of the disease before irreversible changes occur. Methods and Results: Rat heart transplant allograf [...]

by Sigal Shaklai  , Meital Grafi-Cohen  , Orli Sharon  , Gabi Shefer  , Dalia Somjen  and Naftali Stern

Received: 17 April 2019;  Published: 27 August 2019;  doi: 10.21926/obm.transplant.1903082

Background: Estradiol 17-beta (E2) enhances the function and survival of pancreatic beta-cells, but its clinical use has been questioned due to concerns regarding oncogenic potential and feminizing effects in males. The G-protein coupled estrogen receptor (GPER), expressed in pancreatic islets, exhibits estrogenic beta-cell protective effects without the feminizing effects of the nuclear ERs. Here, we examine the outcome of selective activation of the three estrogen receptors ERα, ERβ, and GPER on rep [...]

by Shruthi Kodad  , Waleed Sabry  , Assem Elsayed  , Hadi Goubran  and Mohamed Elemary

Received: 25 June 2019;  Published: 26 August 2019;  doi: 10.21926/obm.transplant.1903081

Hematopoietic stem cell transplant (HSCT) recipients are at an increased risk of bacterial, viral, fungal and parasitic infections. Past exposures to infections, the degree of immunosuppression, prolonged neutropenia and presence of graft versus host disease (GVHD) are some of the factors which make HSCT recipients more susceptible to infections. Viral infections have emerged as a major challenge causing high morbidity and mortality in stem cell transplant recipients. Myeloablative conditioning regimens and GVHD pr [...]

by Scott S. Graves  , DavidW. Mathes  and Rainer Storb

Received: 23 November 2018;  Published: 23 August 2019;  doi: 10.21926/obm.transplant.1903080

Background: The application of hematopoietic cell transplantation for induction of immune tolerance has been limited by toxicities associated with conditioning regimens and to graft-versus-host disease (GVHD). Decades of animal studies have culminated into sufficient control of these two problems, making immune tolerance a viable alternative to life-long application of immunosuppressive drugs to prevent allograft rejection. Methods: Studies in mice have paved the way for the application of HCT with limited toxicity [...]

by Elizabeth F. Wallin  , Michelle A. Linterman  and Kathryn J. Wood

Received: 02 June 2019;  Published: 19 August 2019;  doi: 10.21926/obm.transplant.1903079

Background: T follicular helper (Tfh) and regulatory (Tfr) cells are key players in the formation of long-lived antibody responses. Their circulating counterparts, cTfh and cTfr, are often used as biomarkers because longitudinal sampling of secondary lymphoid tissues is unfeasible in clinical studies. This is the first study to track cTfh and cTfr cells following therapeutic lymphocyte depletion with alemtuzumab, an anti-CD52 monoclonal antibody, to infer the influence of this treatment on the germinal centre respo [...]

by Assaf Assis  , Lena Sapozhnikov  , Sandra Camargo  and Eduardo Mitrani

Received: 07 May 2019;  Published: 14 August 2019;  doi: 10.21926/obm.transplant.1903078

Background: Cell encapsulation technology is most likely the ultimate solution for cell therapy based clinical approaches. A key issue when developing a functional encapsulated construct is to consider not only the nature of the capsule but also how the cells should be incorporated into the capsule in order to minimally compromise their function. Methods: We have developed a tissue engineering approach, composed of decellularized micro scaffolds and various types of cells in which fully functional "Engineered Micro [...]

by Petr A. Fedotov  , Maria A. Simonenko  , Yulia V. Sazonova  , Mariya A. Bortsova  , Artem N. Kostomarov  and Mariya Yu. Sitnikova

Received: 01 February 2019;  Published: 05 August 2019;  doi: 10.21926/obm.transplant.1903077

Background: To estimate the survival of patients in the heart transplantation waiting list (HTx WL) at Almazov National Medical Research Centre (V.A. Almazov NMRC), Saint-Petersburg, Russia, from 2010 to 2017 and to define risk factors for death among these patients. Methods: It was a single-center retrospective study involving 151 patients with advanced chronic heart failure (CHF) in the HTx WL. Results: Mortality in the HTx WL for the period 2010-2017 was found to decrease. Based on the results of constructing th [...]